1. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.
- Author
-
Donnem, T., Kilvaer, T. K., Andersen, S., Richardsen, E., Paulsen, E. E., Hald, S. M., Al-Saad, S., Brustugun, O. T., Helland, A., Lund-Iversen, M., Solberg, S., Gronberg, B. H., Wahl, S. G. F., Helgeland, L., Fløtten, O., Pohl, M., Al-Shibli, K., Sandanger, T. M., Pezzella, F., and Busund, L. T.
- Subjects
- *
TUMOR immunology , *NON-small-cell lung carcinoma , *SURGICAL excision , *ONCOLOGIC surgery , *BREAST cancer , *LYMPHOCYTES - Abstract
Immunoscore is a prognostic tool defined to quantify in situ immune cell infiltrates and appears highly promising as a supplement to the tumor-node-metastasis (TNM) classification of various tumors. In colorectal cancer, an international task force has initiated prospective multicenter studies aiming to implement TNM-Immunoscore (TNM-I) in a routine clinical setting. In breast cancer, recommendations for the evaluation of tumor-infiltrating lymphocytes (TILs) have been proposed by an international working group. Regardless of promising results, there are potential obstacles related to implementing TNM-I into the clinic. Diverse methods may be needed for different malignancies and even within each cancer entity. Nevertheless, a uniform approach across malignancies would be advantageous. In nonsmall-cell lung cancer (NSCLC), there are several previous reports indicating an apparent prognostic importance of TILs, but studies on TILs in a TNM-I setting are sparse and no general recommendations are made. However, recently published data is promising, evoking a realistic hope of a clinical useful NSCLC TNM-I. This review will focus on the TNM-I potential in NSCLC and propose strategies for clinical implementation of a TNM-I in resected NSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF